<p>Kiniksa Pharmaceuticals International（納斯達克股票代碼：KNSA - 獲取免費報告）在週五發佈的報告中，花旗集團的分析師將其目標股價從 45.00 美元上調至 50.00 美元，Benzinga 報道。該公司目前對該股票的評級為 “買入”。花旗集團的目標價暗示該公司當前價格有 31.86% 的上漲潛力。</p>
<p>其他幾位股票分析師最近也對 KNSA 發表了評論。富國銀行將 Kiniksa Pharmaceuticals International 的目標股價從 42.00 美元上調至 45.00 美元，並在 9 月 25 日的報告中給予該股票 “超配” 評級。傑富瑞金融集團在 7 月 29 日的報告中將 Kiniksa Pharmaceuticals International 的目標股價從 45.00 美元上調至 54.00 美元，並給予該股票 “買入” 評級。扎克斯研究在 10 月 6 日的報告中將 Kiniksa Pharmaceuticals International 的評級從 “強力買入” 下調至 “持有”。Wedbush 在週一的報告中將 Kiniksa Pharmaceuticals International 的目標股價從 38.00 美元上調至 44.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重新發布了 Kiniksa Pharmaceuticals International 的 “持有（c）” 評級。七位分析師對該股票給予 “買入” 評級，兩位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 46.86 美元。</p>
<p><strong>查看我們對 Kiniksa Pharmaceuticals International 的最新股票分析</strong></p>
<h2>Kiniksa Pharmaceuticals International 股票表現</h2>
<p>週五中午交易時，KNSA 的股價下跌 1.00 美元，達到 37.92 美元。該股票的交易量為 106,006 股，而其平均交易量為 631,065 股。該公司的市值為 28.1 億美元，市盈率為 948.49，貝塔值為 0.16。Kiniksa Pharmaceuticals International 的 12 個月低點為 17.82 美元，12 個月高點為 39.43 美元。該公司的 50 日移動平均線為 35.72 美元，200 日移動平均線為 29.60 美元。</p>
<p>Kiniksa Pharmaceuticals International（納斯達克股票代碼：KNSA - 獲取免費報告）最後一次發佈季度財報是在 7 月 29 日。該公司報告每股收益為 0.23 美元，超出分析師一致預期的 0.18 美元，超出幅度為 0.05 美元。該公司在該季度的收入為 1.568 億美元，而分析師預期為 1.4521 億美元。Kiniksa Pharmaceuticals International 的淨利潤率為 0.90%，股本回報率為 1.05%。Kiniksa Pharmaceuticals International 已設定其 2025 財年的每股收益指導。研究分析師平均預測 Kiniksa Pharmaceuticals International 在當前財年將發佈-0.55 美元的每股收益。</p>
<h2>Kiniksa Pharmaceuticals International 的內部買賣</h2>
<p>在相關消息中，內部人士 Ross Moat 在 9 月 4 日的交易中出售了 3,523 股公司的股票。該股票以平均價格 35.31 美元出售，總交易額為 124,397.13 美元。出售後，內部人士持有 9,415 股公司股票，價值 332,443.65 美元。這代表其持股比例減少了 27.23%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，首席會計官 Michael R. Megna 在 9 月 3 日的交易中出售了 11,000 股公司的股票。該股票以平均價格 34.84 美元出售，總交易額為 383,240.00 美元。出售後，首席會計官直接持有 38,011 股公司股票，價值約 1,324,303.24 美元。該交易使其持股比例減少了 22.44%。該交易的披露信息可在此找到。在過去的九十天裏，內部人士出售了 596,839 股公司股票，價值 20,357,964 美元。公司內部人士持有 53.48% 的公司股票。</p>
<h2>機構投資者對 Kiniksa Pharmaceuticals International 的看法</h2>
<p>幾家對沖基金和其他機構投資者最近對 KNSA 的持倉進行了調整。GAMMA Investing LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 84.8%。GAMMA Investing LLC 現在擁有 1,238 股公司股票，價值 27,000 美元，此前在該期間內增持了 568 股。Wealth Enhancement Advisory Services LLC 在第一季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值 301,000 美元。Asset Management One Co. Ltd.在第一季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值 41,000 美元。Wealthquest Corp 在第一季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值 42,000 美元。最後，AMI Asset Management Corp 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 50.3%。AMI Asset Management Corp 現在擁有 77,688 股公司股票，價值 1,725,000 美元，此前在該期間內增持了 26,010 股。對沖基金和其他機構投資者持有 53.95% 的公司股票。</p>
<h2>關於 Kiniksa Pharmaceuticals International</h2>
<p>（獲取免費報告）</p>
<p>Kiniksa Pharmaceuticals, Ltd.是一家生物製藥公司，專注於發現、收購、開發和商業化治療藥物，以滿足全球面臨重大未滿足醫療需求的患者的需求。其產品候選包括 ARCALYST，一種針對複發性心包炎的白介素-1α和白介素-1β，複發性心包炎是一種炎症性心血管疾病；Mavrilimumab，一種單克隆抗體抑制劑，已完成鉅細胞動脈炎的二期臨牀試驗；Vixarelimab，一種單克隆抗體，目前正在進行針對結節性瘙癢症的 2b 期臨牀試驗，這是一種慢性炎症性皮膚病；以及 KPL-404，一種 CD40-CD154 相互作用的單克隆抗體抑制劑，這是 B 細胞成熟、免疫球蛋白類別轉換和 1 型免疫反應所需的 T 細胞共刺激信號。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>即將到來的 IPO 股票鎖定期解析</li>
<li>甲骨文的 AI 利潤看起來微薄——NBIS 和 CRWV 也有風險嗎？</li>
<li>內幕交易 - 你需要知道的事項</li>
<li>雅培實驗室十月價格暴跌是買入信號</li>
<li>如何開始投資房地產</li>
<li>為什麼富國銀行的轉型剛剛進入高速檔</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Kiniksa Pharmaceuticals International 嗎？</h2>
<p>在你考慮 Kiniksa Pharmaceuticals International 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Kiniksa Pharmaceuticals International 並不在名單上。</p>
<p>雖然 Kiniksa Pharmaceuticals International 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

KNSA

<p>花旗集團已將 Kiniksa Pharmaceuticals International（納斯達克代碼：KNSA）的目標股價從 45.00 美元上調至 50.00 美元，維持 “買入” 評級。這表明與當前價格相比，潛在上漲幅度為 31.86%。其他分析師也調整了他們的評級，富國銀行將目標上調至 45.00 美元，傑富瑞則上調至 54.00 美元。KNSA 的股票交易價格為 37.92 美元，市值為 28.1 億美元。該公司報告每股收益為 0.23 美元，超出預期，且共識評級為 “適度買入”，平均目標價為 46.86 美元</p>

<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its price target raised by analysts at Citigroup from $45.00 to $50.00 in a report released on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the stock. Citigroup's price objective suggests a potential upside of 31.86% from the company's current price.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International（納斯達克股票代碼：KNSA - 獲取免費報告）在週五發佈的報告中，花旗集團的分析師將其目標股價從 45.00 美元上調至 50.00 美元，Benzinga 報道。該公司目前對該股票的評級為 “買入”。花旗集團的目標價暗示該公司當前價格有 31.86% 的上漲潛力。</p>
</div><p>Several other equities analysts also recently commented on KNSA. Wells Fargo &amp; Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, September 25th. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, July 29th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 6th. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday. Finally, Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $46.86.</p>
<div class="lb-trans"><p>其他幾位股票分析師最近也對 KNSA 發表了評論。富國銀行將 Kiniksa Pharmaceuticals International 的目標股價從 42.00 美元上調至 45.00 美元，並在 9 月 25 日的報告中給予該股票 “超配” 評級。傑富瑞金融集團在 7 月 29 日的報告中將 Kiniksa Pharmaceuticals International 的目標股價從 45.00 美元上調至 54.00 美元，並給予該股票 “買入” 評級。扎克斯研究在 10 月 6 日的報告中將 Kiniksa Pharmaceuticals International 的評級從 “強力買入” 下調至 “持有”。Wedbush 在週一的報告中將 Kiniksa Pharmaceuticals International 的目標股價從 38.00 美元上調至 44.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重新發布了 Kiniksa Pharmaceuticals International 的 “持有（c）” 評級。七位分析師對該股票給予 “買入” 評級，兩位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 46.86 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Kiniksa Pharmaceuticals International</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Kiniksa Pharmaceuticals International 的最新股票分析</strong></p>
</div><h2>Kiniksa Pharmaceuticals International Stock Performance</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 股票表現</h2>
</div><p>Shares of KNSA traded down $1.00 during mid-day trading on Friday, reaching $37.92. The stock had a trading volume of 106,006 shares, compared to its average volume of 631,065. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of 948.49 and a beta of 0.16. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $39.43. The business has a fifty day moving average of $35.72 and a 200 day moving average of $29.60.</p>
<div class="lb-trans"><p>週五中午交易時，KNSA 的股價下跌 1.00 美元，達到 37.92 美元。該股票的交易量為 106,006 股，而其平均交易量為 631,065 股。該公司的市值為 28.1 億美元，市盈率為 948.49，貝塔值為 0.16。Kiniksa Pharmaceuticals International 的 12 個月低點為 17.82 美元，12 個月高點為 39.43 美元。該公司的 50 日移動平均線為 35.72 美元，200 日移動平均線為 29.60 美元。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International（納斯達克股票代碼：KNSA - 獲取免費報告）最後一次發佈季度財報是在 7 月 29 日。該公司報告每股收益為 0.23 美元，超出分析師一致預期的 0.18 美元，超出幅度為 0.05 美元。該公司在該季度的收入為 1.568 億美元，而分析師預期為 1.4521 億美元。Kiniksa Pharmaceuticals International 的淨利潤率為 0.90%，股本回報率為 1.05%。Kiniksa Pharmaceuticals International 已設定其 2025 財年的每股收益指導。研究分析師平均預測 Kiniksa Pharmaceuticals International 在當前財年將發佈-0.55 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 的內部買賣</h2>
</div><p>In related news, insider Ross Moat sold 3,523 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total transaction of $124,397.13. Following the sale, the insider owned 9,415 shares of the company's stock, valued at $332,443.65. This represents a 27.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, CAO Michael R. Megna sold 11,000 shares of the company's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total transaction of $383,240.00. Following the sale, the chief accounting officer directly owned 38,011 shares in the company, valued at approximately $1,324,303.24. The trade was a 22.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 596,839 shares of company stock worth $20,357,964 in the last ninety days. Company insiders own 53.48% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Ross Moat 在 9 月 4 日的交易中出售了 3,523 股公司的股票。該股票以平均價格 35.31 美元出售，總交易額為 124,397.13 美元。出售後，內部人士持有 9,415 股公司股票，價值 332,443.65 美元。這代表其持股比例減少了 27.23%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，首席會計官 Michael R. Megna 在 9 月 3 日的交易中出售了 11,000 股公司的股票。該股票以平均價格 34.84 美元出售，總交易額為 383,240.00 美元。出售後，首席會計官直接持有 38,011 股公司股票，價值約 1,324,303.24 美元。該交易使其持股比例減少了 22.44%。該交易的披露信息可在此找到。在過去的九十天裏，內部人士出售了 596,839 股公司股票，價值 20,357,964 美元。公司內部人士持有 53.48% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>機構投資者對 Kiniksa Pharmaceuticals International 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $301,000. Asset Management One Co. Ltd. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $41,000. Wealthquest Corp purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $42,000. Finally, AMI Asset Management Corp raised its stake in shares of Kiniksa Pharmaceuticals International by 50.3% in the first quarter. AMI Asset Management Corp now owns 77,688 shares of the company's stock valued at $1,725,000 after acquiring an additional 26,010 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對 KNSA 的持倉進行了調整。GAMMA Investing LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 84.8%。GAMMA Investing LLC 現在擁有 1,238 股公司股票，價值 27,000 美元，此前在該期間內增持了 568 股。Wealth Enhancement Advisory Services LLC 在第一季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值 301,000 美元。Asset Management One Co. Ltd.在第一季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值 41,000 美元。Wealthquest Corp 在第一季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值 42,000 美元。最後，AMI Asset Management Corp 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 50.3%。AMI Asset Management Corp 現在擁有 77,688 股公司股票，價值 1,725,000 美元，此前在該期間內增持了 26,010 股。對沖基金和其他機構投資者持有 53.95% 的公司股票。</p>
</div><h2>About Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>關於 Kiniksa Pharmaceuticals International</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals, Ltd.是一家生物製藥公司，專注於發現、收購、開發和商業化治療藥物，以滿足全球面臨重大未滿足醫療需求的患者的需求。其產品候選包括 ARCALYST，一種針對複發性心包炎的白介素-1α和白介素-1β，複發性心包炎是一種炎症性心血管疾病；Mavrilimumab，一種單克隆抗體抑制劑，已完成鉅細胞動脈炎的二期臨牀試驗；Vixarelimab，一種單克隆抗體，目前正在進行針對結節性瘙癢症的 2b 期臨牀試驗，這是一種慢性炎症性皮膚病；以及 KPL-404，一種 CD40-CD154 相互作用的單克隆抗體抑制劑，這是 B 細胞成熟、免疫球蛋白類別轉換和 1 型免疫反應所需的 T 細胞共刺激信號。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Oracle’s AI Profits Look Slim—Are NBIS and CRWV at Risk Too?</li>
<li>Insider Trading - What You Need to Know</li>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
<li>How to Start Investing in Real Estate</li>
<li>Why Wells Fargo's Turnaround Just Hit High Gear</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>即將到來的 IPO 股票鎖定期解析</li>
<li>甲骨文的 AI 利潤看起來微薄——NBIS 和 CRWV 也有風險嗎？</li>
<li>內幕交易 - 你需要知道的事項</li>
<li>雅培實驗室十月價格暴跌是買入信號</li>
<li>如何開始投資房地產</li>
<li>為什麼富國銀行的轉型剛剛進入高速檔</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=KNSA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Kiniksa Pharmaceuticals International 嗎？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Kiniksa Pharmaceuticals International 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Kiniksa Pharmaceuticals International 並不在名單上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kiniksa Pharmaceuticals International 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

花旗集團將 Kiniksa Pharmaceuticals International（NASDAQ 代碼：KNSA）的目標股價上調至 50.00 美元